Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of “Hold” from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned a consensus recommendation of “Hold” from the five research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $5.40.

A number of analysts have recently weighed in on GUTS shares. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Canaccord Genuity Group restated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a report on Thursday. Finally, Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $8.00 to $2.00 in a research report on Thursday, January 29th.

Fractyl Health News Summary

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Q4 2025 results and earnings-call takeaways showed better-than-expected results and operational color that investors liked — management highlighted the quarter and outlook that helped drive upside reaction. Earnings Call Highlights
• Positive Sentiment: Analysts moved more bullish: HC Wainwright raised FY2029–FY2030 EPS estimates and reiterated a Buy with an $8 price target; Canaccord also reaffirmed a Buy and $8 PT — both signals can attract momentum buying given the large implied upside vs. the current price. Analyst Notes (MarketBeat) Canaccord Note
• Positive Sentiment: Shares jumped sharply in after-hours trading (reported ~21% move) on the combination of the results, call and analyst commentary — a clear short-term bullish reaction. After-hours Coverage
• Neutral Sentiment: The full Q4 2025 earnings call transcript is available for investors who want the exact management comments; use it to judge sustainability of the upbeat guidance and timing of any commercial/clinical milestones. Call Transcript
• Neutral Sentiment: Macro and micro risks remain: the consensus for the current fiscal year is still a material loss (analyst consensus ~-1.61 EPS), the stock is low-priced with thin liquidity and is trading below its 50- and 200-day averages — factors that can amplify volatility but not necessarily change the fundamental reaction to positive news.
• Negative Sentiment: The company disclosed a new regulation/compliance risk tied to global anti‑corruption and sanctions laws — this raises potential legal/compliance costs and execution risk that could weigh on valuation if it leads to investigations, fines, or limits on international activity. Compliance Risk Notice

Fractyl Health Price Performance

Shares of GUTS opened at $0.47 on Friday. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $3.03. The firm’s 50 day moving average price is $0.73 and its 200 day moving average price is $1.28. The company has a market cap of $75.07 million, a P/E ratio of -0.26 and a beta of 1.51. The company has a quick ratio of 4.27, a current ratio of 4.78 and a debt-to-equity ratio of 3.23.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.34. On average, research analysts forecast that Fractyl Health will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Fractyl Health

Several hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP lifted its stake in Fractyl Health by 47.2% in the first quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock worth $615,000 after acquiring an additional 165,786 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Fractyl Health in the 2nd quarter valued at approximately $129,000. General Catalyst Group Management LLC acquired a new stake in shares of Fractyl Health in the 2nd quarter valued at $7,912,000. Jane Street Group LLC acquired a new stake in shares of Fractyl Health in the 2nd quarter valued at $31,000. Finally, Osaic Holdings Inc. lifted its position in shares of Fractyl Health by 460.3% during the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock worth $97,000 after purchasing an additional 49,000 shares during the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.